Date: 12/12/2022

Presentation: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.